Earn CME: https://naccme.com/program/19-gdugi-4 In this webcast from the ‘Exploring the Evolving Role of Immunotherapy in Advanced Hepatocellular Carcinoma: Considerations for Therapeutic Selection, Toxicity Management, and Sequencing’ symposium during the 2019 Great Debates & Updates in Gastrointestinal Malignancies conference, Dr. Pashtoon Kasi discusses the best practices for the management of adverse events associated with therapies utilized in the treatment of hepatocellular carcinoma (HCC). © 2019 Imedex, an HMP Company
Managing Adverse Events with New Therapeutic Approaches
